CoChat
Sign Up
Cited by 358Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

Osimertinib for Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

Open access
Cho, Jang Ho, Lim, Sung Hee, An, Ho Jung, Kim, Ki Hwan, Park, Keon Uk, Kang, Eun Joo, Choi, Yoon Hee, Ahn, Mi Sun +6 more·2020·Journal of Clinical Oncology
DOI 10.1200/jco.19.00931PMC PMC7098834
Open this paper in CoChat — free account

Abstract

PURPOSE: Approximately 10% of patients with epidermal growth factor receptor (EGFR) mutation–positive non–small-cell lung cancer (NSCLC) harbor uncommon mutations. Here, we report the efficacy and safety of osimertinib in patients with NSCLC harboring uncommon EGFR mutations. PATIENT AND METHODS: This was a multicenter, single-arm, open-label, phase II study in Korea. Patients with histologically confirmed metastatic or recurrent NSCLC harboring EGFR mutations other than the exon 19 deletion, L858R and T790M mutations, and exon 20 insertion were eligible for the study. The primary end point of objective response rate was assessed every 6 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Secondary end points were progression-free survival, overall survival, duration of response, and safety. RESULTS: Between March 2016 and October 2017, 37 patients were enrolled. All were evaluable except one patient who withdrew consent after starting treatment. Median age was 60 years, and 22 (61%) were male. Among patients, 61% received osimertinib as first-line therapy. The mutations identified were G719X (n = 19; 53%), followed by L861Q (n = 9; 25%), S768I (n = 8; 22%), and others (n = 4; 11%). Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%). Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5 months), and median overall survival was not reached. Median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months). Adverse events of any grade were rash (n = 11; 31%), pruritus (n = 9; 25%), decreased appetite (n = 9; 25%), diarrhea (n = 8; 22%), and dyspnea (n = 8; 22%), but all adverse events were manageable. CONCLUSION: Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

AI snapshot

Written from the paper’s full text.

TL;DR

In this multicenter phase II trial, osimertinib produced an objective response rate of 50% and median progression-free survival of 8.2 months in patients with NSCLC harboring uncommon EGFR mutations, excluding exon 20 insertion. Toxicity was manageable, with grade 3 or 4 adverse events in 6% of patients.

Key findings

  • Among 36 evaluable patients, ORR was 50% (18 of 36; 95% CI, 33% to 67%), disease control rate was 89% (32 of 36; 95% CI, 78% to 100%), and median duration of response was 11.2 months (95% CI, 7.7 to 14.7 months).
  • Median PFS was 8.2 months (95% CI, 5.9 to 10.5 months); median OS was not reached, with 12-month survival 86% (95% CI, 74% to 98%) and 18-month survival 56% (95% CI, 39% to 73%).
  • Subset ORR/PFS: L861Q 78% and 15.2 months; G719X 53% and 8.2 months; S768I 38% and 12.3 months.
  • Any-grade AEs included rash (31%), pruritus (25%), anorexia (25%), diarrhea (22%), and dyspnea (22%); grade 3 or 4 AEs occurred in 2 patients (6%), with no interstitial pneumonitis or QT prolongation.

Methods

  • Multicenter, single-arm, open-label phase II study in Korea (KCSG-LU15-09; NCT03424759); 37 patients were enrolled between March 2016 and October 2017, and 36 who received at least one dose were included in efficacy and safety analyses.
  • Eligible patients had histologically confirmed metastatic or recurrent NSCLC with EGFR mutations other than exon 19 deletion, L858R, T790M, or exon 20 insertion; age 19 years or older; and ECOG performance status 2 or less. Patients received osimertinib 80 mg orally once daily until RECIST 1.1 progression, unacceptable toxicity, or withdrawal of consent.
  • Primary endpoint was ORR by RECIST 1.1 every 6 weeks; secondary endpoints were PFS, OS, DoR, and safety. The study used Simon’s two-stage optimal design (90% power, one-sided alpha of .05; rule out 10% and target 30% objective response), with Kaplan-Meier analysis for time-to-event endpoints.

Limitations

  • Stated by the paper: local EGFR testing with PCR-based or direct sequencing methods may have limited sensitivity for detecting compound EGFR mutations compared with next-generation sequencing; the study included both first-line and later-line treatment, so a more homogeneous group should be investigated; and the limited number of patients for each uncommon EGFR mutation subtype warrants larger studies.
  • Evident from the text: this was a small, single-arm study without a randomized comparator, and the uncommon EGFR mutation population is heterogeneous, making subset analyses based on very few patients difficult to interpret.
  • Evident from the text: CNS response analysis excluded 4 of 9 patients with CNS metastasis because they received gamma knife surgery or whole-brain radiotherapy along with osimertinib, leaving only 5 evaluable patients for intracranial ORR.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1200/jco.19.00931

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 26 cited sources checked · 0 supported · 0 flagged

  • Findingown data
    § Ef fi cacy

    Among five evaluable patients, intracranial ORR was 40% (2 of 5).

    “Among the fi ve evaluable patients, intracranial ORR was 40% (2 of 5 patients).”
    Quote in the paperNot a substantial claim
  • Findingown data
    § Osimertinib for Patients With Non -Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Median overall survival was not reached.

    “median overall survival was not reached”
    • Also stated in: § Ef fi cacy · plain
      “the median OS was not reached”
    Quote in the paperNot a substantial claim
  • Findingown data
    § Ef fi cacy

    Tumor shrinkage was observed in 28 patients (78%).

    “Tumor shrinkage was observed in 28 patients (78%; Fig 2).”
    Quote in the paperSubstantial claim
  • Findingown data
    § Osimertinib for Patients With Non -Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    The objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%).

    “Objective response rate was 50% (18 of 36 patients; 95% CI, 33% to 67%).”
    • Also stated in: § Ef fi cacy · plain
      “The ORR was 50% (18 of 36 patients; 95% CI, 33% to 67%)”
    Quote in the paperSubstantial claim
  • Findingown data
    § Safety

    Grade 3 or 4 AEs were observed in two patients (6%).

    “Grade 3 or 4 AEs were only observed in two patients (6%).”
    Quote in the paperNot a substantial claim
  • May combine two claims. 23
  • Classified as probably not a substantial claim. 14
  • The quote only partly states this claim. 5

  • May combine two claims.

    Findingown data
    § Ef fi cacy

    The 12-month survival rate was 86% and the 18-month survival rate was 56%.

    “The 12-month survival rate was 86% (95% CI, 74% to 98%), and the 18-month survival rate was 56% (95% CI, 39% to 73%).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data
    § Ef fi cacy

    Objective responses were noted in 78% of patients with L861Q, 53% with G719X, and 38% with S768I.

    “Objective responses were noted in 78% of patients with the L861Q mutation, followed by 53% with G719X and 38% for S768I (Table 2).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data
    § Ef fi cacy

    PFS of patients with L861Q, G719X, or S768I mutations was 15.2 months, 8.2 months, and 12.3 months, respectively.

    “PFS of patients with L861Q, G719X, or S768I mutations was 15.2 months (95% CI, 1.3 to 29.1 months), 8.2 months (95% CI, 6.2 to 10.2 months), and 12.3 months (95% CI, 0 to 28.8 months), respectively.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data
    § Demographics

    The most common uncommon EGFR mutation was G719X (53%), followed by L861Q (25%) and S768I (22%).

    “The most common uncommon EGFR mutation was G719X (53%), followed by L861Q (25%) and S768I (22%).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data
    § Ef fi cacy

    The proportion of patients progression free at 6 and 12 months was 64% and 39%, respectively.

    “The proportion of patients who were progression free at 6 and 12 months was 64% (95% CI, 47% to 80%) and 39% (95% CI, 22% to 56%), respectively.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S1 (asserted), S4 (based). The quote only partly states this claim.

    Findingown data
    § DISCUSSION

    In patients with L861Q mutation, median progression-free survival was 15.2 months.

    “our results demonstrated an ORR of 78% and a PFS of 15.2 months”
    Quote in the paperNot a substantial claim

  • The quote only partly states this claim.

    Findingown data
    § DISCUSSION

    Median progression-free survival was 8.2 months (95% CI, 5.9 to 10.5) in 36 patients with NSCLC harboring uncommon EGFR mutations treated with osimertinib.

    “The ORR was 50% and the median PFS was 8.2 months among a total of 36 patients.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S1 (asserted), S4 (based).

    Findingown data
    § DISCUSSION

    In patients with L861Q mutation, osimertinib produced an objective response rate of 78%.

    “our results demonstrated an ORR of 78% and a PFS of 15.2 months”
    Quote in the paperNot a substantial claim

  • The quote only partly states this claim.

    Findingown data
    § DISCUSSION

    In patients with G719X mutation, median progression-free survival was 8.2 months.

    “In the current study, ORR and PFS were 53% and 8.2 months, respectively.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data
    § Safety

    No patients suffered from interstitial pneumonitis or QT prolongation.

    “No patients suffered from interstitial pneumonitis or QT prolongation.”
    Quote in the paperNot a substantial claim

  • The quote only partly states this claim.

    Findingown data
    § DISCUSSION

    Osimertinib produced an objective response rate of 50% (95% CI, 33% to 67%) in 36 patients with NSCLC harboring uncommon EGFR mutations.

    “The ORR was 50% and the median PFS was 8.2 months among a total of 36 patients.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation
    § INTRODUCTION

    Osimertinib is an oral, third-generation, irreversible EGFR-TKI that selectively inhibits both sensitizing EGFR mutations and T790M resistance mutations.

    “Osimertinib is an oral, third-generation, irreversible EGFR-TKI that selectively inhibits both sensitizing EGFR mutations and Thr790Met (T790M) resistance mutations.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [11] source

      Not checked in the free run.

    • cites [12] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductown data
    § Study Design and Participants

    The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice, and the protocol was approved by institutional review boards with written informed consent.

    “This study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. The study protocol and all amendments were approved by all associated institutional review boards. All patients provided written informed consent.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data
    § Demographics

    Excluding one patient who withdrew consent, 36 patients were included in the efficacy and safety analyses.

    “Excluding one patient who withdrew consent, 36 patients were included in the ef fi cacy and safety analyses (Fig 1).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Study design and conductcitation
    § Statistical Analysis

    The study used Simon's two-stage phase II optimal design with 90% power and one-sided alpha .05 to rule out a 10% objective response and target a 30% objective response.

    “The statistical design of the study was based on Simon ' s two-stage phase II optimal design (power of 90% and one-sided a of .05) to rule out a 10% objective response and to target a 30% objective response.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [27] source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation
    § INTRODUCTION

    A post hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 showed clinical activity of afatinib in patients with advanced NSCLC harboring uncommon EGFR mutations, especially G719X, L861Q, and S768I, but low activity against T790M and exon 20 insertion mutations.

    “showed clinical activity of afatinib in patients with advanced NSCLC harboring uncommon EGFR mutations, especially Gly719Xaa (G719X), Leu861Gln (L861Q), and Ser768Ile (S768I), but low activity against T790M and exon 20 insertion mutations.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [26] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation
    § DISCUSSION

    Response rates to EGFR TKIs in patients with NSCLC with sensitizing EGFR mutations (exon 19 deletions or L858R) are approximately 60% to 80%.

    “Response rates to EGFR TKIs in patients with NSCLC with sensitizing EGFR mutations (exon 19 deletions or L858R) are approximately 60% to 80%, 3,5”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [3] source

      Not checked in the free run.

    • cites [5] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    In a post hoc analysis by Yang et al, ORR to afatinib was 56%, with a PFS of 8.2 months in patients with L861Q mutation.

    “In a post hoc analysis by Yang et al, 26 ORR to afatinib was 56%, with a PFS of 8.2 months.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [26] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    Wu et al documented an ORR of 53.3% and a PFS of 8.1 months in patients with G719X mutation who were treated with gefitinib or erlotinib.

    “Wu et al 25 documented an ORR of 53.3% and a PFS of 8.1 months in patients with G719X mutation who were treated with ge fi tinib or erlotinib.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [25] source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    In preclinical studies, the L861Q mutation is resistant to first-generation TKIs, whereas it might be sensitive to afatinib or osimertinib.

    “In preclinical studies, the L861Q mutation is resistant to fi rst-generation TKIs, whereas it might be sensitive to afatinib or osimertinib. 28-31”
    Quote in the paperSubstantial claim0 of 4 sources checked
    • cites [28] source

      Not checked in the free run.

    • cites [29] source

      Not checked in the free run.

    • cites [30] source

      Not checked in the free run.

    • cites [31] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data
    § Osimertinib for Patients With Non -Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase II Trial (KCSG-LU15-09)

    Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

    “Osimertinib demonstrated favorable activity with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The 36 patients enrolled are representative of the broader population of patients with NSCLC harboring uncommon EGFR mutations.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductreasoning
    § DISCUSSION

    The applied polymerase chain reaction-based or direct sequencing methods might have had limitations for the detection of compound EGFR mutations because of low sensitivity compared with next-generation sequencing.

    “The applied polymerase chain reaction -based or direct sequencing methods might have had limitations for the detection of compound EGFR mutations because of low sensitivity compared with nextgeneration sequencing.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    With afatinib, an ORR of 77.8% and a PFS of 13.8 months were reported in patients with G719X mutation.

    “In contrast, with afatinib, an ORR of 77.8% and a PFS of 13.8 months were reported. 26”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [26] source

      Not checked in the free run.

  • May combine two claims.

    Interpretationown data
    § DISCUSSION

    Osimertinib was associated with a high response rate, an encouraging PFS, and a long DoR with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.

    “Osimertinib was associated with a high response rate, an encouraging PFS, and a long DoR with manageable toxicity in patients with NSCLC harboring uncommon EGFR mutations.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    In two phase II studies of patients with T790M-positive NSCLC and CNS metastasis, osimertinib demonstrated a CNS ORR of 54% and a CNS disease control rate of 92%.

    “In two phase II studies of patients with T790Mpositive NSCLC and CNS metastasis, osimertinib demonstrated a CNS ORR of 54% and a CNS disease control rate of 92%. 17”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [17] source

      Not checked in the free run.

  • May combine two claims. The quote only partly states this claim.

    Interpretationown data
    § DISCUSSION

    Osimertinib produced better clinical outcomes (ORR 78%, PFS 15.2 months) than other uncommon mutations in patients with L861Q mutation.

    “our results demonstrated an ORR of 78% and a PFS of 15.2 months, which are better clinical outcomes than with other uncommon mutations.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given
    § DISCUSSION

    Both first-line treatment and additional lines of therapy were included in this study.

    “since both fi rst-line treatment and additional lines of therapy were included”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    Osimertinib has a higher CNS ORR and a longer CNS PFS than gefitinib and erlotinib in the treatment of CNS metastases in patients with EGFR-mutated NSCLC.

    “Osimertinib has a higher CNS ORR and a longer CNS PFS than ge fi tinib and erlotinib in the treatment of CNS metastases in patients with EGFR-mutated NSCLC, as shown by the results from the phase III FLAURA trial.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites FLAURA trial

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation
    § DISCUSSION

    In the AURA3 phase III trial, osimertinib demonstrated significantly higher efficacy than platinum-based chemotherapy in patients with T790M-positive NSCLC.

    “In the AURA3 phase III trial, osimertinib demonstrated signi fi cantly higher ef fi cacy than platinum-based chemotherapy in patients with T790M-positive NSCLC. 14”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [14] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning
    § DISCUSSION

    The enhanced blood-brain barrier penetrance of osimertinib may explain the higher CNS responses observed in patients with NSCLC.

    “The enhanced blood -brain barrier penetrance of osimertinib may explain the higher CNS responses observed in patients with NSCLC.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation
    § DISCUSSION

    Chiu et al reported that among 54 patients with NSCLC harboring L861Q mutations, ORR was 40% and PFS was 8.1 months with first-generation TKI erlotinib or gefitinib.

    “Chiu et al 32 reported the largest cohort of patients with NSCLC harboring L861Q mutations. Among 54 patients, ORR was 40% and PFS was 8.1 months with the fi rst-generation TKI erlotinib or ge fi tinib.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [32] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation
    § DISCUSSION

    With afatinib, ORR was 100% (8 of 8) and median PFS was 14.7 months in patients with S768I mutation.

    “In contrast, with afatinib, ORR was 100% (8 of 8) and median PFS was 14.7 months.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [26] source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation
    § DISCUSSION

    Wu et al reported that objective responses to gefitinib or erlotinib were observed in 57.1% of patients with Gly719 or Leu861 mutations, with a PFS of 6.0 months.

    “Wu et al 25 reported that objective responses to ge fi tinib or erlotinib were observed in 57.1% of patients with Gly719 or Leu861 mutations, with a PFS of 6.0 months.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [25] source

      Not checked in the free run.

33 of 33

  • The paper relies on this without support.

    The 36 patients enrolled are representative of the broader population of patients with NSCLC harboring uncommon EGFR mutations.

    “Between March 2016 and October 2017, a total of 37 patients were enrolled from 7 institutes in Korea.”
    “Excluding one patient who withdrew consent, 36 patients were included in the ef fi cacy and safety analyses (Fig 1).”

  • The paper relies on this without support.

    Uncommon EGFR mutations constitute a heterogeneous group of genetic alterations.

    “given that uncommon EGFR mutations constitute a heterogeneous group of genetic alterations”

  • The paper relies on this without support.

    Uncommon EGFR mutations have low prevalence.

    “because of the high molecular heterogeneity and low prevalence”
3 of 3

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Patients with atypical EGFR mutations show heterogeneous and reduced responses to EGFR inhibitors, including osimertinib.

    “Patients with atypical EGFR mutations show heterogeneous and reduced responses to EGFR inhibitors1,3,7–10, including osimertinib12.”

    From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Excluded exon 20 insertion appears in the study cohort

    Major

    The study says it excluded exon 20 insertions, but Table 1 lists one participant with an exon 20 insertion.

1 of 1

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Cho, J. H., Lim, S. H., An, H. J., Kim, K. H., Park, K. U., Kang, E. J., Choi, Y. H., Ahn, M. S., Lee, M. H., Sun, J.-M., Lee, S.-H., Ahn, J. S., Park, K., & Ahn, M.-J.
Affiliations
  • Samsung Medical Center (KR)
  • Soonchunhyang University Hospital Bucheon (KR)
  • The Catholic University of Korea St. Vincent's Hospital (KR)
  • Seoul National University Hospital (KR)
  • Korea University Medical Center (KR)
  • Dongnam Institute of Radiological & Medical Sciences (KR)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2020-02-10
Volume
38
Issue
5
Pages
488-495
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.19.00931
PMC
PMC7098834
OpenAlex
W2995864319
Semantic Scholar
b1d6b796a41f87aabd48fd6f0cd3f16582128403
Cited by
358
References
32
Citations by year
2026: 25 · 2025: 38 · 2024: 51 · 2023: 59 · 2022: 68 · 2021: 56 · 2020: 57 · 2019: 4
FWCI
34.01
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • AJOU Open Repository (Ajou University) (submittedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords
non-small cell lung cancer, EGFR mutation, uncommon EGFR mutations, G719X mutation, L861Q mutation, EGFR tyrosine kinase inhibitors, first-line therapy, objective response rate, progression-free survival, adverse events, rash, pruritus, metastatic lung cancer, recurrent lung cancer
MeSH terms
Progression-Free Survival, Acrylamides, Administration, Oral, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Metastasis, Neoplasm Recurrence, Local, Pyrimidines, Survival Rate, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-06.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-06.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review